EVALUATING THE CROSS-OVER EFFECT ON HEALTH-RELATED QUALITY OF LIFE IN A RANDOMIZED CROSS-OVER STUDY OF HEMOPHILIA-A PATIENTS

Author(s)

Jo H1, Gringeri A2, Leissinger C3, Mantovani L4, Cortesi P5, Gemmen E11Quintiles, Rockville, MD, USA, 2University of Milan, Milano, Italy, 3Tulane University, New Orleans, LA, USA, 4Federico II University of Naples, Naples , Italy, 5Fondazione CHARTA, Mil

OBJECTIVES:   To investigate the cross-over effects on health-related quality of life (HRQoL) in an randomized cross-over design study for hemophilia-A patients. METHODS: HRQoL via SF-36 Health Survey was measured every 3 months in a prospective, randomized, cross-over, investigator-initiated study comparing 6 months of AICC infused prophylaxis (PX) with 6 months of on-demand (OD) therapy, separated by a 3-month washout period during which patients used on-demand therapy. HRQoL was summarized in two continuous variables: Physical Component Score (PCS-36) and Mental Component Score (MCS-36). The difference between two study periods for 6-month change from baseline in PCS-/MCS-36 are compared using Wilcoxon signed-rank test to measure the difference between two groups regardless of the sequence of medications. To investigate the effect of random sequence in the change of HRQoL, the difference between two study periods for 6-month change from baseline in PCS-/MCS-36 is compared by random sequence using Wilcoxon-Mann-Whitney U test with exact statement.  RESULTS:  Twenty-six patients completed both study periods.  17 of them were >14 years old and thus completed QoL questionnaires and are included in this analysis. The difference between PX and OD in 6-month change from baseline was 2.83 for PCS-36 (p=0.378) and 1.29 for MCS-36 (p=0.890), favored PX on both measures. Regardless of random sequence of medication, HRQoL showed a moderate improvement with PX. When comparing the difference of 6-month change by treatment sequence, patients who initiated with PX then switched to OD had a greater improvement compared to the opposite sequence (PX->OD: 6.59, OD->PX: 0.19 for PCS-36 (p=0.475); PX→OD: 2.66, OD→PX: 0.33 for MCS-36 (p=0.601)). CONCLUSIONS: A cross-over effect, albeit statistically non-significant, was observed when the difference of 6-month change was compared by treatment sequence. Patients who started with more favorable medication tended to show a greater improvement, whereas patients in opposite sequence showed a slight improvement. 

Conference/Value in Health Info

2011-11, ISPOR Europe 2011, Madrid, Spain

Value in Health, Vol. 14, No. 7 (November 2011)

Code

PSY47

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×